DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

  -- advertisement --

Testing the Nocturnal Sleep Latency Profile in Primary Insomnia

Information source: University of Pittsburgh
Information obtained from ClinicalTrials.gov on October 19, 2007
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Primary Insomnia; Sleep Initiation and Maintenance Disorders

Intervention: eszopiclone 3 mg qHS (Drug); General cognitive/behavioral interventions for insomnia (Behavioral)

Status: Recruiting

Sponsored by: University of Pittsburgh

Official(s) and/or principal investigator(s):
Douglas E Moul, M.D., M.P.H, Principal Investigator, Affiliation: University of Pittsburgh

Overall contact:
Robin Richardson, LCSW, Phone: (412) 246-6400, Email: richardsonrj@upmc.edu

Summary

This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.

Clinical Details

Official title: Testing the Nocturnal Sleep Latency Profile in Primary Insomnia

Study design: Observational, Natural History, Cross-Sectional, Case Control, Prospective Study

Detailed description: Patients are carefully screened to have DSM primary insomnia, and do not have another disorder than may cause a sleep disturbance. After a 2-week baseline period, the subjects undergo a screening sleep study to rule out sleep apnea and periodic limb movement disorder. Then they undergo the NSLP procedure. In that procedure, there pre-bedtime EEG recordings and questionnaire responses taken. Then at a planned time, the subjects go to bed and try to sleep while there EEG signals are recorded. After the first and second sleep cycles, they are awakened for one minute, then asked to return to sleep. In the morning additional recordings and questionnaire responses are obtained. Two nights later they repeat a baseline NSLP procedure. The controls then end their participation. The Patients then receive an open treatment with eszopiclone and behavioral treatments so that their insomnia may improve. After 2 weeks intervention, the patients complete one NLSP night. The goal of the study is to see if there can be data to support the idea that the sleep onset process might harbor a sign of primary insomnia that could be used for the development of a better medical model of primary insomnia.

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Primary Insomnia (N = 12) Age & Gender matched Healthy controls (N = 12)

Exclusion Criteria:

- Unstable Medical illness No other Sleep disorder BMI > 35, AHI > 10, PLM Index > 10, Ferritin < 50. Unable to communicate in English

Locations and Contacts

Robin Richardson, LCSW, Phone: (412) 246-6400, Email: richardsonrj@upmc.edu

Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania 15213, United States; Recruiting
Robin Richardson, LCSW, Phone: 412-246-6400, Email: richardsonrj@upmc.edu
Douglas E Moul, M.D., M.P.H., Principal Investigator
Daniel J Buysse, M.D., Sub-Investigator
Additional Information

Starting date: January 2005
Ending date: September 2005
Last updated: September 7, 2006

Page last updated: October 19, 2007

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008